Huadong Medicine's Sinclair Gains EU MDR CE Certification for Injectable KIO015

Huadong Medicine announced that KIO015, an injectable carboxymethyl chitosan solution featuring a new patented ingredient and developed by its UK wholly-owned subsidiary Sinclair Pharma Limited, has obtained EU MDR CE certification, securing market access to the European Union. The product is the world's first and currently the only innovative non-animal-derived chitosan aesthetic injection product.